These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 8150755)

  • 21. A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial.
    Arcieri G; Griffith E; Gruenwaldt G; Heyd A; O'Brien B; Screen P; Becker N; August R
    J Clin Pharmacol; 1988 Feb; 28(2):179-89. PubMed ID: 3360968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients.
    Eggimann P; Glauser MP; Aoun M; Meunier F; Calandra T
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():151-63. PubMed ID: 8150759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new therapeutic option for the treatment of pneumonia.
    McCabe R; Chirurgi V; Farkas SA; Haddow A; Heinz G; Greene S
    Am J Med; 1996 Jun; 100(6A):60S-67S. PubMed ID: 8678099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ceftazidime in severe infections: a Swiss multicentre study.
    Francioli P; Clément M; Geroulanos S; von Graevenitz A; Luthy R; Regamey C; Stalder H; Vogt M; Waldvogel FA
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():139-46. PubMed ID: 6225761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection.
    Lau SM; Peng MY; Chang FY
    J Microbiol Immunol Infect; 2004 Jun; 37(3):185-91. PubMed ID: 15221039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cefepime: a new fourth-generation cephalosporin.
    Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
    Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter, double-blind, randomized clinical trial of parenterally administered Cefoselis versus Cefepime for the treatment of acute bacterial infections.
    Liu YB; Lv XJ; Yu RJ; Qiu HM; Bai JL; Jiang N; Lin JM; Liu YJ; Yan HY; Song SD; He P; Guo DY; Li XS
    Eur Rev Med Pharmacol Sci; 2014; 18(14):2006-12. PubMed ID: 25027339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia.
    Schrank JH; Kelly JW; McAllister CK
    Clin Infect Dis; 1995 Jan; 20(1):56-8. PubMed ID: 7727671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
    Wagenlehner FM; Gasink LB; McGovern PC; Moeck G; McLeroth P; Dorr M; Dane A; Henkel T;
    N Engl J Med; 2024 Feb; 390(7):611-622. PubMed ID: 38354140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Activity of cefepime compared with other antibiotics against major hospital bacterial pathogens].
    Hryniewicz W; Skoczyńska A; Szczypa K
    Pol Merkur Lekarski; 2001 Feb; 10(56):80-2. PubMed ID: 11320582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefepime.
    Hardin TC; Jennings TS
    Pharmacotherapy; 1994; 14(6):657-68. PubMed ID: 7885968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with the fourth generation cephalosporins.
    Giamarellou H
    J Chemother; 1996 Feb; 8 Suppl 2():91-104. PubMed ID: 8738851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Laboratory and clinical studies on S-1108 in the pediatric field].
    Akita H; Yokota T; Sunakawa K; Iwata S; Satoh Y
    Jpn J Antibiot; 1993 Nov; 46(11):967-77. PubMed ID: 8309073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin.
    Segreti J; Levin S
    Am J Med; 1996 Jun; 100(6A):45S-51S. PubMed ID: 8678097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cefepime (maxipime) in the treatment of severe urinary tract infection].
    Derevianko II
    Antibiot Khimioter; 2003; 48(7):24-8. PubMed ID: 14628575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment.
    Chang SC; Fang CT; Hsueh PR; Liu CJ; Sheng WH; Hsieh SM; Hung CC; Chen YC
    Int J Antimicrob Agents; 1998 Aug; 10(3):245-8. PubMed ID: 9832286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study of bacteraemia in cancer patients. Results of a French multicentre study.
    Escande MC; Herbrecht R
    Support Care Cancer; 1998 May; 6(3):273-80. PubMed ID: 9629882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi.
    Arsalan A; Naqvi SB; Ali SA; Ahmed S; Shakeel O
    Pak J Pharm Sci; 2015 May; 28(3):841-7. PubMed ID: 26004702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.